Table 1 Risk factors and histopathologic characteristics of HNC cases (N = 109)1 by baseline HPV-16 E6/E7 status
Characteristics | HPV-16 E62 | Adjusted OR5 | HPV-16 E73 | Adjusted OR5 | HPV-16 E6 and/or E74 | Adjusted OR5 | |||
|---|---|---|---|---|---|---|---|---|---|
Positive n (%) | Negative n (%) | Positive n (%) | Negative n (%) | Positive n (%) | Negative n (%) | ||||
Gender | |||||||||
Male | 15 (68.2) | 52 (59.8) | 3.0 (0.9-9.4) | 15 (75.0) | 52 (58.4) | 3.4 (1.01-11.5) | 17 (65.4) | 50 (60.2) | 1.9 (0.7-5.2) |
Female | 7 (31.8) | 35 (40.2) | 1.0 | 5 (25.0) | 37 (41.6) | 1.0 | 9 (34.6) | 33 (39.8) | 1.0 |
Age Group | |||||||||
≤ 55 years | 14 (63.6) | 30 (34.5) | 2.7 (0.96-7.7) | 12 (60.0) | 32 (36.0) | 2.7 (0.9-7.6) | 15 (57.7) | 29 (34.9) | 2.5 (0.97-6.6) |
> 55 years | 8 (36.4) | 57 (65.5) | 1.0 | 8 (40.0) | 57 (64.0) | 1.0 | 11 (42.3) | 54 (65.1) | 1.0 |
Number of Partners | |||||||||
0-2 | 7 (33.3) | 35 (43.7) | 1.0 | 6 (33.3) | 36 (43.4) | 1.0 | 9 (37.5) | 33 (42.9) | 1.0 |
3-9 | 5 (23.8) | 23 (28.8) | 1.4 (0.4-5.7) | 4 (22.2) | 24 (28.9) | 1.3 (0.3-5.6) | 5 (20.8) | 23 (29.9) | 1.0 (0.3-3.6) |
≥ 10 | 9 (42.9) | 22 (27.5) | 6.9 (1.5-33.2) | 8 (44.4) | 23 (27.7) | 5.6 (1.2-26.5) | 10 (41.7) | 21 (27.3) | 4.5 (1.1-18.6) |
Pack years | |||||||||
Never | 6 (27.3) | 23 (26.4) | 1.0 | 4 (20.0) | 25 (28.1) | 1.0 | 6 (23.1) | 23 (27.7) | 1.0 |
≤ 30 | 12 (54.5) | 14 (16.1) | 4.0 (1.1-14.1) | 10 (50.0) | 16 (18.0) | 4.6 (1.2-18.3) | 12 (46.2) | 14 (16.9) | 4.1 (1.2-14.3) |
> 30 | 4 (18.2) | 50 (57.5) | 0.4 (0.1-1.8) | 6 (30.0) | 48 (53.9) | 1.1 (0.2-4.7) | 8 (30.8) | 46 (55.4) | 1.0 (0.3-3.5) |
Drinks per Week | |||||||||
Never | 6 (27.3) | 28 (32.2) | 1.0 | 5 (25.0) | 29 (32.6) | 1.0 | 7 (26.9) | 27 (32.5) | 1.0 |
≤ 21 | 10 (45.5) | 34 (39.1) | 2.0 (0.6-6.6) | 9 (45.0) | 35 (39.3) | 1.8 (0.5-6.1) | 12 (46.2) | 32 (38.6) | 1.7 (0.6-5.2) |
> 21 | 6 (27.3) | 25 (28.7) | 3.7 (0.8-18.1) | 6 (30.0) | 25 (28.1) | 2.5 (0.6-11.3) | 7 (26.9) | 24 (28.9) | 2.0 (0.5-7.8) |
Tumor Site | |||||||||
Oropharynx | 20 (90.9) | 7 (8.1) | 51.9 (2.7-1007.0)6 | 16 (80.0) | 11 (12.4) | 4.1 (0.5-32.6) | 20 (76.9) | 7 (8.4) | 7.9 (1.04-60.8) |
Oral Cavity | 2 (9.1) | 71 (81.6) | 0.7 (0.03-14.9)6 | 2 (10.0) | 71 (79.8) | 0.1 (0.01-0.7)6 | 4 (15.4) | 69 (83.1) | 0.2 (0.02-1.2)6 |
Larynx\hypopharynx | 0 (0.0) | 9 (10.3) | 1.0 | 2 (10.0) | 7 (7.9) | 1.0 | 2 (7.7) | 7 (8.4) | 1.0 |
Oropharynx vs. Oral Cavity | 19.7 (5.3-73.9)7 | 10.1 (2.9-35.8)7 | 24.2 (1.5-384.0)7 | ||||||
Stage | |||||||||
I/II | 2 (9.1) | 38 (43.7) | 1.0 | 1 (5.0) | 39 (43.8) | 1.0 | 3 (11.5) | 37 (44.6) | 1.0 |
III/IV | 20 (90.9) | 49 (56.3) | 23.7 (4.2-133.6) | 19 (95.0) | 50 (56.2) | 26.2 (3.1-221.8) | 23 (88.5) | 46 (55.4) | 11.3 (2.8-45.8) |
Tumor Size | |||||||||
T0-T2 | 18 (81.8) | 45 (52.9) | 1.0 | 13 (65.0) | 50 (57.5) | 1.0 | 19 (73.1) | 44 (54.3) | 1.0 |
T3-T4 | 4 (18.2) | 40 (47.1) | 0.3 (0.1-1.04) | 7 (35.0) | 37 (42.5) | 0.9 (0.3-2.6) | 7 (26.9) | 37 (45.7) | 0.5 (0.2-1.4) |
Grade | |||||||||
Poor/Undifferentiated | 11 (50.0) | 14 (16.1) | 5.5 (1.8-17.1) | 9 (45.0) | 16 (18.0) | 3.7 (1.3-11.1) | 12 (46.2) | 13 (15.7) | 4.8 (1.7-13.7) |
Well/Moderate | 11 (50.0) | 73 (83.9) | 1.0 | 11 (55.0) | 73 (82.0) | 1.0 | 14 (53.8) | 70 (84.3) | 1.0 |
Nodal Involvement | |||||||||
Yes | 20 (90.9) | 31 (35.6) | 37.3 (6.8-204.3) | 17 (85.0) | 34 (38.2) | 11.3 (2.8-45.1) | 21 (80.8) | 30 (36.1) | 9.4 (2.9-30.0) |
No | 2 (9.1) | 56 (64.4) | 1.0 | 3 (15.0) | 55 (61.8) | 1.0 | 5 (19.2) | 53 (63.9) | 1.0 |
HPV DNA | |||||||||
High-Risk | 20 (90.9) | 10 (11.5) | 22.0 (6.2-77.2)7 | 16 (80.0) | 14 (15.7) | 27.8 (7.2-107.8) | 21 (80.8) | 9 (10.8) | 60.1 (13.9-259.4) |
Type 16 | 19 (90.5) | 9 (10.5) | 25.1 (6.6,-95.2)7 | 16 (80.0) | 12 (13.9) | 32.5 (8.2-129.6) | 20 (80.0) | 8 (9.0) | 58.0 (13.7-246.3) |
Type 33 | 1 (0.4) | 1 (1.0) | NE | 0 (0.0) | 2 (1.8) | NE | 1 (0.8) | 1 (1.8) | NE |
Negative | 2 (9.1) | 77 (88.5) | 1.0 | 4 (20.0) | 75 (84.3) | 1.0 | 5 (19.2) | 74 (89.2) | 1.0 |